Building on these initial results, we combined αPD-1 with an immune stimulatory and ECM degrading oncolytic Ad, which coexpresses interleukin (IL)-12, granulocyte macrophage colony-stimulating factor (GM-CSF), and RLX, to elicit potent and durable antitumor immune responses against pancreatic cancer. This evidence concerns the gene CSF2 and familial pancreatic carcinoma.